Preclinical & Non-Clinical Support Services
Our preclinical and non-clinical support services provide comprehensive safety, pharmacokinetic, and efficacy evaluation to advance compounds from discovery into clinical development. We support pharmaceutical, biotechnology, and translational research programs with scientifically rigorous, regulator-aligned studies that reduce development risk and support IND and CTA submissions.
All studies are designed and executed in accordance with OECD guidelines, global regulatory expectations, and best laboratory practices. We are ISO Certified Contract Research Oorganization (ISO 9001:2015)
Toxicology & Safety Pharmacology
We offer a full spectrum of toxicology and safety pharmacology services to characterize compound safety profiles across acute, repeat-dose, and long-term exposure scenarios.-
Acute Toxicity Studies
-
Subacute & Subchronic Toxicity
-
Chronic Toxicity
-
Reproductive & Developmental Toxicity
-
Carcinogenicity Studies
-
Neurotoxicity
-
Immunotoxicity
-
Local Tolerance Studies
-
Safety Pharmacology
-
Genotoxicity Testing – GLP Certified
Acute Toxicity Studies
We conduct single-dose acute toxicity studies in compliance with OECD 420, 423, and 425, supporting early hazard identification and dose selection.
Subacute & Subchronic Toxicity
Our repeat-dose toxicity studies include 14 day range-finding and 28 and 90 day studies in alignment with OECD 407, 408, and 409.
Chronic Toxicity Studies
We perform chronic toxicity studies ranging from 6 to 12 months in accordance with OECD 452, supporting long-term exposure evaluation.
Reproductive & Developmental Toxicity
We support reproductive and developmental toxicity (DART) programs, including Segments I, II, and III, aligned with OECD 414, 416, 421, 422, and 443.
Carcinogenicity Studies
Our carcinogenicity testing includes two-year rodent bioassays conducted in line with OECD 451 and 453.
Neurotoxicity
We provide neurotoxicity studies using the Functional Observation Battery (FOB) framework in accordance with OECD 424.
Immunotoxicity
Our immunotoxicity assessments include T-dependent antibody response (TDAR) testing to evaluate immune system modulation.
Genotoxicity Testing – GLP Compliant
Evaluation of genetic damage potential using validated in-vitro and in-vivo assays in alignment with OECD, ICH, and regulatory authority requirements.
Local Tolerance Studies
We conduct local tolerance testing, including skin, eye, and mucosal irritation studies, to evaluate formulation safety.
Safety Pharmacology
Our safety pharmacology services assess potential effects on cardiovascular, respiratory, and central nervous systems (CNS) in line with regulatory guidance.
Pharmacokinetics & ADME Services
We deliver integrated pharmacokinetics and ADME services to characterize exposure, disposition, and metabolic pathways.-
ADME Profiling
-
Pharmacokinetic Studies
-
Bioavailability & Bioequivalence
-
Tissue Distribution
-
Metabolite Identification
-
Drug–Drug Interaction Studies
ADME Profiling
We perform comprehensive ADME profiling to evaluate absorption, distribution, metabolism, and excretion characteristics.
Pharmacokinetic Studies
Our pharmacokinetic studies include single-dose, multiple-dose, and cassette dosing designs to support dose optimization and exposure assessment.
Bioavailability & Bioequivalence
We conduct bioavailability and bioequivalence studies, including IV/PO crossover designs, in OECD-compliant frameworks.
Tissue Distribution
We support tissue distribution studies using quantitative whole-body autoradiography (QWBA) to assess organ exposure.
Metabolite Identification
Our laboratory capabilities include metabolite identification using LC-MS/MS and NMR, supporting safety and DDI assessment.
Drug–Drug Interaction Studies
We conduct drug–drug interaction (DDI) studies to evaluate metabolic and transporter-mediated interaction risks.
Genotoxicity Assessment
We provide validated genotoxicity testing services to assess genetic safety and regulatory compliance.-
Ames Test – OECD 471
-
Micronucleus Assay – OECD 474
-
Comet Assay – OECD 487
Ames Test – OECD 471
The Ames test evaluates mutagenic potential in accordance with OECD Guideline 471.
Micronucleus Assay – OECD 474
Our micronucleus assay (OECD 474) detects chromosomal damage and aneugenic events.
Comet Assay – OECD 489
The Comet assay assesses DNA strand breaks at the single-cell level, following OECD 489 standards.
In Vivo Pharmacology & Efficacy Models
Our in vivo pharmacology and efficacy models support proof-of-concept, dose justification, and translational relevance. These models enable robust evaluation of therapeutic efficacy and mechanistic relevance.-
Oncology models
-
Central nervous system (CNS) disease models
-
Inflammatory and autoimmune disease models
-
Cardiovascular and metabolic disease models
-
Immunology and infection models
Why Choose Our Preclinical & Non-Clinical Support?
Broad toxicology, PK, and efficacy expertise
OECD-aligned, IND-enabling study designs
Integrated safety, ADME, and in vivo pharmacology
Support across discovery to first-in-human programs